Compare BETR & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BETR | ALLO |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 492.2M | 539.4M |
| IPO Year | N/A | 2018 |
| Metric | BETR | ALLO |
|---|---|---|
| Price | $29.09 | $2.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | ★ $40.00 | $8.36 |
| AVG Volume (30 Days) | 351.7K | ★ 4.5M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $51.61 | N/A |
| Revenue Next Year | $62.67 | $141,204.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.50 | $0.86 |
| 52 Week High | $94.06 | $2.80 |
| Indicator | BETR | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 42.96 | 57.05 |
| Support Level | $25.33 | $1.01 |
| Resistance Level | $35.07 | $2.80 |
| Average True Range (ATR) | 3.85 | 0.19 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 2.32 | 48.33 |
Better Home & Finance Holding Co is a digital-first homeownership company whose services include mortgage, real estate, title, and homeowners insurance. The company has combined technology innovation and fresh thinking with a deep customer focus with the goal of revolutionizing the homeownership industry.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.